Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuhan Chung

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Oncotarget|April 9, 2016
PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reactionDaniel R Principe, Brian DeCant, Andrew M Diaz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Cell Reports. Medicine|April 19, 2023
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASHJake Conway, Maryam Pouryahya, Yevgeniy Gindin, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Gut|January 12, 2012
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in micePaul J Grippo, Philip S Fitchev, David J Bentrem, et al.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Cell|October 14, 2022
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASHMasaki Kimura, Takuma Iguchi, Kentaro Iwasawa, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Oncotarget|April 9, 2016
PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reactionDaniel R Principe, Brian DeCant, Andrew M Diaz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Cell Reports. Medicine|April 19, 2023
Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASHJake Conway, Maryam Pouryahya, Yevgeniy Gindin, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Gut|January 12, 2012
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in micePaul J Grippo, Philip S Fitchev, David J Bentrem, et al.
Gastroenterology|July 31, 2018
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, et al.
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Cell|October 14, 2022
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASHMasaki Kimura, Takuma Iguchi, Kentaro Iwasawa, et al.
Pageof 7